Resveratrol Trial for Relief of Pain in Pseudoachondroplasia
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Pseudoachondroplasia
In brief
The purpose of this study is to determine if self-administered oral resveratrol can dampen joint pain for individuals with pseudoachondroplasia compared to placebo. Another goal of this study is to evaluate side effects in this population.
Key facts
- Study ID
- NCT03866200
- Run by
- The University of Texas Health Science Center, Houston
- People needed
- 6
- Starts
- 2019-06-29
- Expected to finish
- 2020-10-28
- Last updated by the study team
- 2022-12-09
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- The diagnosis of pseudoachondroplasia is based on clinical assessment either in person or by photographic review by skeletal dysplasia specialist (JTH),
- Healthy beyond pseudoachondroplasia associated complications,
You may not qualify if…
- Current use of resveratrol
- Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine and triazolam.
- Other non-pseudoachondroplasia related health conditions, e.g. cancers.
- Pregnancy or breastfeeding. Women must use adequate contraception during the study.
- Participation in another clinical study and/or using investigational agents.
- Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin.
- Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine, Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir, Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine, Fosphenytoin, Phenytoin or Warfarin.
- Baseline level of pain of 2 or higher on 10 point scale.
- Platelet count below 50,000 per ul on baseline complete blood count (CBC).
Where it is running
- University of Texas Health Science Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.